Top 25 Spotlight: nymble Health

Supporting the Patient Between Clinic Visits

Managing long-term weight health is a daily, deeply personal journey, yet patients are often left to navigate it alone. When individuals are prescribed metabolic medications like GLP-1s, they step out of the clinic and into a behavioral vacuum. Between doctor visits—when the critical work of managing side effects, resisting misinformation, and rewriting habits actually happens—there is rarely anyone in their corner.

To fill this void, the tech sector usually defaults to building another app. But for millions navigating chronic metabolic conditions, a new download introduces friction rather than relief. Forced to navigate complex logins and rigid tracking, users quickly drop off; standard digital health apps routinely lose up to 70% of their active user base within the first 90 days.

That behavioral chasm is exactly what Vancouver-based nymble Health is designed to bridge. Founded by frontline clinicians Dr. Puneet Seth and Dr. Megha Poddar, nymble abandons the app model entirely in favor of frictionless, text-based care. By integrating personalized behavioral support directly into channels patients already use daily—like standard SMS and WhatsApp—nymble provides an omnipresent, judgment-free clinical companion with zero learning curve.

The structural urgency of scaling this effective infrastructure is clear. According to Obesity Canada, adult obesity affects nearly one in three Canadians, and a recent landmark analysis revealed that the “cost of inaction” in treating the disease has reached a staggering $27.6 billion annually in healthcare spending, disability costs, and lost workplace productivity. By transforming an isolated prescription into a continuous, data-backed relationship, nymble ensures patients don’t disappear when early obstacles hit, injecting vital support into a system that needs it most.

The Enterprise Traction Engine

What They’ve Done: nymble Health has completely bypassed the speculative phase of digital health development by deploying its platform across heavy-hitting enterprise ecosystems. The startup has locked in over a dozen brand-name customers and partners, including major pharmacy networks like Shoppers Drug Mart and Rexall, alongside advocacy bodies like Obesity Canada and virtual care platforms like RocketDoctor. Delivering over 100,000 patient interactions to date, nymble has generated a massive pipeline nearing $2 million and is currently live across four countries: Canada, Germany, Ireland, and the United States.

The core driver behind this commercial momentum is nymble’s ability to solve the industry’s retention crisis. While standard digital health apps typically lose most of their users within 90 days, an unprecedented 65% of nymble users remain actively engaged at the six-month mark. In real-world European deployments, this sustained connection has transformed clinical outcomes—driving a 26% improvement in GLP-1 medication persistence at six months in Ireland, and a 21% boost in treatment retention at three months in Germany.

Why NVBC: Moving through the 2026 New Ventures BC Competition, presented by Innovate BC, has pushed the team to translate deep clinical authority into a highly optimized commercial business case. Presenting to non-clinical panels and tech mentors forced the founders to sharpen how they articulate capital efficiency and market timing, while opening critical deployment and funding channels throughout Western Canada’s technology ecosystem.

Up Next: Over the next 12 months, the Vancouver startup is focused on establishing its platform as the enterprise standard for metabolic behavioral support. The team aims to sign three anchor contracts spanning life sciences and corporate insurer benefit plans, while simultaneously publishing peer-reviewed data from their global pilots. A core objective for 2026 is validating the “nymble score” as an adopted clinical industry metric for measuring ongoing behavior change.

The Distribution Truth

The hardest lesson the nymble team has learned is a reality many founders overlook: in healthcare, distribution is the product. Even the most sophisticated clinical tool will fail to scale if it doesn’t enter a patient’s life through a foundation of established trust.

Instead of spending millions on direct-to-consumer marketing to acquire single users, nymble focuses entirely on enterprise partnerships. By ensuring that every stakeholder wins—physicians get better data, pharmacists secure higher medication persistence, and payers reduce wasted spend—nymble embeds itself directly into existing healthcare workflows, allowing organic B2B distribution to compound naturally.